Tianze Yuntai

Tianze Yuntai is a clinical-stage biotechnology company headquartered in Beijing, China, dedicated to the development of transformative gene therapies. The company focuses on utilizing its proprietary adeno-associated virus (AAV) vector platform to address rare genetic diseases and chronic conditions with high unmet medical needs. Its lead candidate, VGB-R04, is an AAV-based gene therapy currently in Phase 1/2 clinical trials for the treatment of Hemophilia B. Beyond hematology, Tianze Yuntai is advancing a diverse pipeline targeting metabolic disorders like Pompe disease and Fabry disease, as well as ophthalmic indications such as wet age-related macular degeneration. The company integrates internal R&D with large-scale GMP manufacturing capabilities to accelerate the delivery of genetic medicines. Founded by industry veterans and gene therapy pioneers, Tianze Yuntai is backed by prominent venture capital investors.